Table 1.
Patient and tumor characteristics in the two subsequently blended cohorts. (Abbreviations: F = female, M = male, HIV = human immunodeficiency virus, DFS = disease-free survival).
| Bordeaux Cohort (n = 36) | FFCD Cohort (n = 46) | p-Value | |
|---|---|---|---|
| Age at diagnosis (mean, years) | 62.3 | 60.1 | 0.39 |
| Sex: | 0.96 | ||
| - F | 30/36 (83.3%) | 37/46 (80.4%) | |
| - M | 6/36 (16.7%) | 9/46 (19.6%) | |
| HIV status: | 0.79 | ||
| - Positive | 1/36 (2.8%) | 3/46 (6.5%) | |
| - Negative | 35/36 (97.2%) | 43/46 (93.5%) | |
| Tumor length (mean, mm) | 51.2 | 47.5 | 0.40 |
| Pre-rectal tumor infiltration | 16/36 (44.4%) | 13/46 (28.2%) | 0.20 |
| T-stage: | 0.44 | ||
| - cT1-2 | 11/36 (30.6%) | 19/46 (41.2%) | |
| - cT3-4 | 25/36 (69.4%) | 27/46 (58.7%) | |
| N-stage: | 1 | ||
| - cN0 | 10/36 (27.8%) | 12/46 (26.1%) | |
| - cN+ | 26/36 (72.2%) | 34/46 (73.9%) | |
| AJCC groupings: | 0.20 | ||
| - I | 1/36 (2.8%) | 0/46 (0%) | |
| - IIa | 4/36 (11.1%) | 5/46 (10.9%) | |
| - IIb | 1/36 (2.8%) | 4/46 (8.7%) | |
| - IIIa | 6/36 (16.7%) | 14/46 (30.4%) | |
| - IIIb | 4/36 (11.1%) | 3/46 (6.5%) | |
| - IIIc | 20/36 (55.5%) | 20/46 (43.5%) | |
| 2-year DFS | 23/36 (63.9%) | 35/46 (76.1%) | 0.34 |